Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
Revolution Medicines is seeking an Executive Director of GCP QA to set and execute the global GCP quality strategy across clinical development programs. The role ensures compliance with regulatory requirements, industry standards, and company policies governing clinical trials.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
Apogee Therapeutics